Key result
WAY-123,398 increased the ventricular fibrillation threshold and induced defibrillation in 2 of 6 anesthetized dogs, comparable to UK-68798 (2 of 6) and E-4031 (1 of 6).
Why the study?
Does WAY-123,398 improve cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs compared to other Class III antiarrhythmic agents?
Population
Open-chest anesthetized dogs
Comparison
WAY-123,398 vs UK-68798, E-4031, dl-sotalol, and vehicle
Design
Preclinical
Authors
Loading...
Does not support clinical adoption; leaves open further evaluation in arrhythmia models.
Does WAY-123,398 improve cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs compared to other Class III antiarrhythmic agents?
WAY-123,398 is an effective Class III antiarrhythmic agent with a favorable hemodynamic profile that increases ventricular fibrillation threshold in a canine model.
Spinelli et al. (1992) studied Anesthetized dogs. WAY-123,398 vs. UK-68798, E-4031, dl-sotalol, and vehicle was evaluated on Cardiac refractoriness and ventricular fibrillation threshold. WAY-123,398 increased the ventricular fibrillation threshold and induced defibrillation in 2 of 6 anesthetized dogs, comparable to UK-68798 (2 of 6) and E-4031 (1 of 6).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: